2 months ago
PEN
AnalystsDavid RescottDavid Rescott's Stock Forecasts
AnalystsDavid Rescott
Sectors:
Analyst Ranking
Top 19%
#903 out of 4906 analysts
Average Return
+7.73%
Win Rate
54%30 out of 56
Risk vs Reward
Poor
Good
David Rescott's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Penumbra IncPEN | +141.93% | $124.98 | $302.36 | 2022-07-20 - 2023-07-19 | Strong Buy |
Inari Medical IncNARI | +70.64% | $46.56 | $79.45 | 2024-07-31 - 2025-01-07 | Buy |
Si Bone IncSIBN | +65.40% | $12.08 | $19.98 | 2022-12-20 - 2023-12-19 | Strong Buy |
Inari Medical IncNARI | +61.55% | $49.18 | $79.45 | 2024-10-29 - 2025-01-07 | Buy |
Boston Scientific CorpBSX | +55.49% | $53.97 | $83.92 | 2023-09-21 - 2024-09-20 | Buy |
David Rescott Analyst Color
Get additional color on David Rescott's coverage of popular stocks
4 months ago
PEN
a year ago
SIBN
a year ago
PEN
a year ago
AXNX
2 years ago
PEN
David Rescott's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Medtronic PLCMDT | 5 | Hold | $92.00 | +5.42% | Maintains | 25 days ago |
Livanova PLCLIVN | 3 | Buy | $61.00 | +33.30% | Maintains | a month ago |
Merit Medical Systems IncMMSI | 3 | Buy | $110.00 | +18.32% | Maintains | 2 months ago |
Penumbra IncPEN | 28 | Strong Buy | $330.00 | +28.65% | Maintains | 2 months ago |
Edwards Lifesciences CorpEW | 4 | Hold | $75.00 | -0.20% | Maintains | 2 months ago |
Boston Scientific CorpBSX | 5 | Buy | $120.00 | +20.31% | Maintains | 2 months ago |
Intuitive Surgical IncISRG | 3 | Buy | $575.00 | +12.27% | Maintains | 2 months ago |
Inari Medical IncNARI | 4 | Hold | $80.00 | +0.04% | Downgrades | 5 months ago |
Axonics IncAXNX | 8 | Hold | $71.00 | N/A | Downgrades | a year ago |
Si Bone IncSIBN | 5 | Strong Buy | $26.00 | N/A | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.